Full-Time

Associate Director

Multiple Teams

Posted on 9/10/2026

Deadline 9/24/26
AstraZeneca

AstraZeneca

10,001+ employees

Global pharmaceutical company developing prescription medicines

Compensation Overview

$151.1k - $226.6k/yr

+ Short-term incentive bonus + Equity-based long-term incentive program

Boston, MA, USA

Hybrid

Three days in the office per week are required.

Bachelor's, Master's, MBA

Category
Growth & Marketing (1)
Required Skills
Data Analysis

Get referred to AstraZeneca

See people who can refer or advise you

Requirements
  • Three to five or more years of professional pharmaceutical or biotechnology experience in competitive market landscapes.
  • Direct experience leading peer-to-peer marketing, speaker bureau management, and/or healthcare professional education initiatives.
  • Strong healthcare professional marketing experience, including experience navigating Promotional Review Committee and medical, legal, and regulatory review processes.
  • Understanding of pharmaceutical industry compliance guidelines, including the Office of Inspector General and Pharmaceutical Research and Manufacturers of America Code, as they relate to speaker programs and healthcare professional engagement.
  • Experience in rare disease, specialty, or high-value biologics.
  • Demonstrated project management skills, including the ability to manage multiple high-priority initiatives, agencies, and vendors simultaneously.
  • Ability to learn and demonstrate scientific and business acumen.
  • Ability to collaborate and influence without authority in a highly matrixed organization.
  • Verbal, written, and live presentation communication skills.
  • Ability to work in a rapidly evolving, fast-paced environment.
  • A bachelor's degree is required.
  • Ability to work at least three days in the office each week.
  • Ability to travel at least 25% of the time, including overnight travel to speaker programs, congresses, and internal meetings.
  • Ability to use a computer, communicate through phone, video, and electronic messaging, solve problems, perform analysis and non-linear thought and dialogue, collaborate with others, and maintain general availability during standard business hours.
Responsibilities
  • Lead the development and execution of annual and long-range peer-to-peer marketing strategies, tactics, and budgets across generalized Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder indications, aligned with brand imperatives and healthcare professional educational needs.
  • Coordinate end-to-end management of the national speaker bureaus for generalized Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder, including speaker nomination, training, content development, program deployment, utilization optimization, and compliance oversight with Medical, Legal, Regulatory, and Compliance.
  • Lead the development and Promotional Review Committee approval of peer-to-peer educational content and tactics, including live speaker programs, peer-to-peer broadcasts, webinars, digital peer-to-peer experiences, and related healthcare professional communications.
  • Partner with brand teams, the Thought Leader Liaison team, and Congress Management to plan and execute peer-exchange forums at national and regional neurology congresses, including product theaters, exhibits, symposia, and advisory boards.
  • Lead the planning and execution of advisory boards across generalized Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder, including defining objectives, developing discussion guides, identifying and engaging participants with Medical and Thought Leader Liaisons, and translating insights into brand strategies.
  • Partner with generalized Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder healthcare professional marketing leads to ensure peer-to-peer initiatives are insight-driven, brand-aligned, and integrated across the rare neurology portfolio.
  • Collaborate with the Thought Leader Liaison team to identify and cultivate speakers, capture field and key opinion leader insights, and translate those insights into peer-to-peer programming and content evolution.
  • Coordinate peer-to-peer program timelines, agency partners, vendor logistics, and budgets across both indications.
  • Partner with Commercial Insights and Analytics to define key performance indicators, monitor program performance, evaluate impact on healthcare professional behavior, and optimize peer-to-peer investments.
  • Develop and maintain collaborative relationships with Field Sales, Training, OneSource, Promotional Review Committee, Medical, Regulatory, Clinical, Legal, Compliance, and Market Access to ensure compliant, high-quality execution.
  • Drive presentation content and marketing communications through written and oral presentations to commercial and medical leadership, Rare Neurology leadership, and commercial sales meetings.
Desired Qualifications
  • An advanced degree or Master of Business Administration.
  • Neurology, rare disease, or specialty/high-value biologics marketing experience.
  • United States commercial launch experience.
  • Diverse commercial experience, such as field sales, operations, or Thought Leader Liaison experience.
  • Experience with promotional platforms such as Veeva PromoMats.
  • Analytical skills to inform investment decisions and metrics-based optimization of healthcare professional education programs.

AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Get referred to AstraZeneca

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • EU approved Enhertu plus pertuzumab on September 1, 2026, unlocking another breast-cancer line.
  • Amgen and AstraZeneca’s DeLLphi-305 met overall-survival goals for Imdelltra plus Imfinzi.
  • AstraZeneca committed £300 million in April 2026 to Cambridge and Macclesfield expansion.

What critics are saying

  • Reuters on August 17, 2026 said AstraZeneca ended volrustomig’s lung-cancer trial after futility.
  • China indicted Leon Wang and AstraZeneca’s local unit in February 2026; trial risk persists.
  • Forxiga faces patent losses in Poland, Portugal, Australia, and 2027 generic-launch pressure.

What makes AstraZeneca unique

  • AstraZeneca’s 2026 cancer franchise spans Imfinzi, Tagrisso, Enhertu, and Datroway globally.
  • Its UK-Sweden operating base supports Cambridge and Macclesfield R&D plus manufacturing.
  • Daiichi Sankyo and Amgen partnerships broaden AstraZeneca’s reach without full internal capital burden.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

4%
Yahoo Finance
Sep 11th, 2026
Cramer avoids AstraZeneca as trial failures and regulatory pressures overshadow $15.4B revenue

Jim Cramer stated on Mad Money that he is not investing in AstraZeneca, comparing it to Novartis and expressing concerns about missed clinical trials. He believes the company's COPD programme is insufficient to change his view. AstraZeneca reported second-quarter revenue of $15.38 billion, up 6.4% year-on-year, with adjusted earnings per share of $2.63 beating estimates. Growth was driven by oncology and rare disease treatments, offsetting generic competition. However, the company faces significant challenges. The drug anselamimab failed its primary endpoint in a Phase III trial, whilst datopotamab deruxtecan delivered mixed results in lung cancer studies. AstraZeneca's blockbuster drug Farxiga will face a 68% Medicare price reduction from 2026 under the Inflation Reduction Act. The company also contends with regulatory investigations in China involving senior executives.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

The Telegraph
Sep 9th, 2026
AstraZeneca buys biotech company for £120m

Drug giant AstraZeneca has agreed to buy KuDOS Pharmaceuticals, a UK biotech company, for $210mn (£120m).

Yahoo Finance
Sep 8th, 2026
AstraZeneca shares slip 0.7% despite Imfinzi trial success in lung cancer treatment

AstraZeneca shares declined approximately 0.7% to $161.51 despite positive late-stage trial results for Imfinzi in treating extensive-stage small-cell lung cancer. The 563-patient DeLLphi-305 trial met its primary overall-survival goal when Imfinzi was combined with Amgen's Imdelltra, also improving progression-free survival and response rates with no new safety concerns. However, the companies have not released numerical survival data, leaving investors unable to assess the treatment's competitive strength. Imfinzi generated $6.06 billion in 2025, whilst oncology represented approximately 46% of AstraZeneca's $30.7 billion first-half 2026 revenue. The shares now trade 10.72% below their $180.91 valuation estimate. AstraZeneca must share economics with Amgen and demonstrate that the treatment's added complexity can convert into meaningful sales growth.

Executive Bulletin
Sep 7th, 2026
First Oncology Summit in Lebanon hosted by AstraZeneca brings together regional experts to advance the Future of Cancer Care.

First Oncology Summit in Lebanon hosted by AstraZeneca brings together regional experts to advance the Future of Cancer Care. September 7, 2026 Beirut, 7 September 2026: The first Oncology Summit hosted by AstraZeneca in Lebanon under the theme "Leading the Future in Cancer Care" brought together leading oncology experts from Lebanon and Libya, alongside international faculty members, for two days of scientific exchange and collaboration focused on advancing cancer care and improving patient outcomes. The summit featured discussions on evolving standards of care, emerging scientific advances, and multidisciplinary approaches across lung cancer, gastrointestinal cancers, breast cancer, and ovarian cancer. "Scientific meetings such as this are essential to advancing oncology practice," said Dr. Arafat Tfayli, President of the Committee Responsible for Implementing Lebanon's National Cancer Control Plan. "They allow healthcare professionals to exchange experiences, discuss the latest evidence, and learn from regional and international experts. By strengthening collaboration and sharing knowledge, we can continue to elevate the quality of care available to patients across our region." "The challenges we face in cancer care are shared across many countries, and so too are the opportunities for progress," said Dr. Abdelmnam Elbarathi, Director of Tripoli Cancer Center, speaking on behalf of the Lybian delegation. "Bringing together experts from Libya and Lebanon creates meaningful opportunities for collaboration, learning, and professional exchange that can ultimately contribute to better care for patients. We look forward to strengthening these connections and continuing to work together to advance oncology practice throughout the region." The landmark event underscored AstraZeneca's commitment to supporting the oncology community through innovation, science, and partnerships, while reinforcing Lebanon's role as a regional platform for medical excellence and scientific dialogue. "Lebanon has long been recognized for its medical expertise, and we are proud to contribute to its role as a hub for scientific leadership and innovation," said Agnar Aboujaoude, Country Director, AstraZeneca Lebanon, who emphasized the power of collaboration in shaping the future of oncology care. "We are proud to bring together distinguished oncology experts from Lebanon, Libya, and the international scientific community around a shared purpose: improving the lives of patients with cancer. By fostering scientific exchange and regional collaboration, we can help accelerate the adoption of best practices, strengthen healthcare ecosystems, and ultimately bring new hope to patients and their families." The summit provided a platform for healthcare professionals to exchange knowledge, review emerging evidence, discuss real-world clinical experiences, and explore innovative approaches that are helping redefine cancer care worldwide. Throughout the discussions, participants examined the evolving oncology landscape and the opportunities to improve outcomes through earlier diagnosis, precision medicine, multidisciplinary care, and continued scientific advancement. "At AstraZeneca, our ambition is to eliminate cancer as a cause of death," said Mark Farid, Oncology Commercial Director for Near East & Maghreb at AstraZeneca, highlighting the company's long-term commitment to transforming cancer care through scientific innovation. "We continue to invest in one of the industry's broadest oncology portfolios and pipelines, advancing innovative science across multiple tumour types and treatment modalities. Through collaboration with healthcare professionals, researchers, and healthcare systems, we are working to transform outcomes and bring patients closer to a future where cancer can be detected earlier, treated more effectively, and, ultimately, cured." About AstraZeneca: AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.